TRC8 Activators

Activators of TRC8, as detailed in the table, are a group of chemicals that primarily function by modulating protein degradation pathways, such as the ubiquitin-proteasome system and ERAD. They prevent the degradation of ubiquitinated proteins or induce ER stress, thereby indirectly promoting the ubiquitin ligase activity of TRC8. Proteasome inhibitors like MG132, Bortezomib, Lactacystin, Carfilzomib, and Epoxomicin prevent the degradation of ubiquitinated proteins, creating a backlog of substrates for ubiquitin ligases including TRC8. This backlog indirectly enhances the function of TRC8, as it has more opportunities to ubiquitinate its substrates.

On the other hand, Chloroquine, ALLN, Leupeptin, and Concanamycin A inhibit lysosomal protein degradation, again leading to an increase in ubiquitinated proteins that TRC8 can act on. Further, Thapsigargin, Tunicamycin, and Eeyarestatin I induce ER stress, thereby activating the ERAD pathway. This pathway is significant because TRC8 is an ERAD E3 ubiquitin ligase and its activity can be enhanced in response to the activation of this pathway. Hence, these activators, despite not being direct, can still promote TRC8's function by increasing the number of its potential substrates or by activating cellular stress responses that TRC8 is inherently involved in.